Polypoidal choroidal vasculopathy - Pipeline Insight, 2025

DelveInsight’s, “Polypoidal choroidal vasculopathy - Pipeline Insight, 2025” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Polypoidal choroidal vasculopathy pipeline and Polypoidal choroidal vasculopathype. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Polypoidal choroidal vasculopathy: Understanding

Polypoidal choroidal vasculopathy: Overview

Polypoidal choroidal vasculopathy (PCV) is an ocular condition primarily affecting the choroid, which is the vascular layer of the eye. This disease is characterized by abnormal blood vessels that can lead to significant vision impairment. Polypoidal choroidal vasculopathy (PCV) commonly presents with sudden blurring of vision or the development of a scotoma, which manifests as a blind spot in central vision. These symptoms can affect one or both eyes, significantly impacting the patient’s ability to perform daily tasks. Another frequent symptom is metamorphopsia, where straight lines appear distorted or wavy. Unlike some other ocular conditions, the visual disturbances associated with PCV are typically stable throughout the day and do not exhibit significant fluctuation.

PCV is characterized by abnormal, polyp-like structures in the choroidal blood vessels, leading to serosanguineous retinal pigment epithelial detachments. These abnormalities are thought to arise from dysfunctions in the inner choroidal vessels. Although the exact cause of PCV remains unclear, it is believed to have a multifactorial etiology that involves both genetic and environmental factors. PCV shares some clinical and pathological features with wet age-related macular degeneration (AMD), suggesting a potential overlap in their underlying mechanisms.

Diagnosing PCV requires a thorough dilated fundus examination conducted by an ophthalmologist, often complemented by advanced imaging techniques. Indocyanine green angiography (ICGA) is the gold standard diagnostic tool, offering detailed visualization of choroidal blood vessels and their abnormalities. Fluorescein angiography is another commonly used imaging modality, providing insight into retinal blood flow and leakage patterns. Additionally, optical coherence tomography (OCT), a non-invasive imaging technique, is crucial for assessing retinal structure, detecting fluid accumulation, and monitoring disease progression over time.

The treatment of PCV focuses on controlling symptoms and preventing further vision loss. Photodynamic therapy (PDT) is a targeted approach that involves injecting a photosensitizing agent, followed by laser activation to selectively treat abnormal blood vessels. Anti-VEGF therapy, consisting of intravitreal injections of medications that inhibit vascular endothelial growth factor, is another cornerstone treatment, effectively reducing fluid leakage and bleeding. In some cases, thermal laser therapy may be considered, though it is less commonly used due to potential side effects. For patients without active symptoms or significant disease progression, observation with regular monitoring may be recommended to avoid unnecessary interventions.

""Polypoidal choroidal vasculopathy - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Polypoidal choroidal vasculopathy pipeline landPolypoidal choroidal vasculopathype is provided which includes the disease overview and Polypoidal choroidal vasculopathy treatment guidelines. The assessment part of the report embraces, in depth Polypoidal choroidal vasculopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Polypoidal choroidal vasculopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Polypoidal choroidal vasculopathy R&D. The therapies under development are focused on novel approaches to treat/improve Polypoidal choroidal vasculopathy.

Polypoidal choroidal vasculopathy Emerging Drugs Chapters

This segment of the Polypoidal choroidal vasculopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Polypoidal choroidal vasculopathy Emerging Drugs

ABI-110: Avirmax Biopharma

ABI-110 is a novel gene therapy developed by Avirmax Biopharma, currently undergoing Phase I/IIa clinical trials for the treatment of wet age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV). This therapy employs an engineered adeno-associated virus capsid, AAV2.N54, to deliver a therapeutic transgene directly to the macular retina, targeting the genetic underpinnings of these conditions rather than merely alleviating symptoms as traditional treatments do. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of polypoidal choroidal vasculopathy.

Further product details are provided in the report…….

Polypoidal choroidal vasculopathy: Therapeutic Assessment

This segment of the report provides insights about the different Polypoidal choroidal vasculopathy drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Polypoidal choroidal vasculopathy

There are approx. 3+ key companies which are developing the therapies for Polypoidal choroidal vasculopathy. The companies which have their Polypoidal choroidal vasculopathy drug candidates in the most advanced stage, i.e. Phase I/II include, Avirmax Biopharma.

• Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Polypoidal choroidal vasculopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Polypoidal choroidal vasculopathy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Polypoidal choroidal vasculopathy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Polypoidal choroidal vasculopathy drugs.

Polypoidal choroidal vasculopathy Report Insights

• Polypoidal choroidal vasculopathy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Polypoidal choroidal vasculopathy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Polypoidal choroidal vasculopathy drugs?
• How many Polypoidal choroidal vasculopathy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Polypoidal choroidal vasculopathy?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Polypoidal choroidal vasculopathy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Polypoidal choroidal vasculopathy and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Avirmax Biopharma
• Novartis

Key Products

• ABI-110
• Brolucizumab